Proximal Humerus FracturePosttraumatic Arthrosis After Humeral Head FracturePosttraumatic Necrosis of the Humeral Head
Study summary
The study is a multicenter, retrospective and prospective, non-randomized, non-controlled and consecutive series post-market study. The purpose of this study is to collect long-term data confirming safety, performance and clinical benefits of the Anatomical Shoulder 2.0 Fracture System (Implants and Instrumentation) when used for fracture shoulder arthroplasty. The primary objective is the assessment of safety by analyzing implant survivorship. This will be established by recording the incidence and frequency of revisions, complications and adverse events. Relation of the events to implant, instrumentation and/or procedure should be specified.
The secondary objective is the assessment of performance and clinical benefits by recording patient-reported clinical outcome measures (PROMs) as well as radiographic outcomes.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients 18 years or older and skeletally mature
* Patients capable of understanding the surgeon's explanations and following his instructions, able and willing to participate in the follow-up program and who gave consent to take part in the study
* Replacement of the proximal humerus and the glenoid articular surface of the scapula during total-, hemi- and fracture shoulder arthroplasty in treatment of the following:
1. Complex 3- and 4- part fractures of the proximal humerus with subluxation of the head fragment
2. Complex 3- and 4- part fractures of the proximal humerus with loosening of the spongiosa in the head fragment
3. Complex 3- and 4- part fractures of the proximal humerus with additional cross split of the head fragment
4. Fracture instability after osteosynthesis of 3- and 4-part fracture fragments of the proximal humerus
5. Posttraumatic necrosis of the humeral head
6. Posttraumatic arthrosis after humeral head fracture
Exclusion Criteria:
* Patients who are unwilling or unable to give consent, not willing to return for study required follow-up visits and/or to comply with the follow-up program.
* The patient is known to be pregnant or breastfeeding
* Patients who have any condition that would in the judgment of the Investigator place the patient at undue risk or interfere with the study.
* Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, anticipated to be non-compliant).
* Patients with plans to relocate during the study follow-up period
* Signs of infection
* Extensive stiffening of the shoulder joint without pain
Primary outcome measure(s)
Incidence and frequency of revisions [Product safety based on implant survivorship] — 3-10 years Safety will be assessed by recording and analyzing the incidence and frequency of revisions, complications and adverse events. A Kaplan Meier survival curve will be calculated.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.